PSTX Live signals | Maximize Profits with Getagraph.com

BUY 99490 min ago

@ $3.72

Issued: 14 Feb 2024 @ 11:00

Return: -41.26%

Previous signal: Feb 13 - 15:15

Previous signal: Sell

Return: 1.36 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 14:10):

Stats
Today's Volume	184 413
Average Volume	747 937
Market Cap	210.83M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.340 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.590
ATR14	$0.00400 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Rizvi Syed Ali-aamir	Buy	250 000	Employee Stock Option (Right to Buy)
2024-04-01	Rizvi Syed Ali-aamir	Buy	185 000	Common Stock
2024-04-01	Rizvi Syed Ali-aamir	Buy	0
2024-03-01	Mylet Johanna	Buy	80 743	Common Stock
2024-03-01	Mylet Johanna	Sell	18 091	Common Stock

INSIDER POWER
88.73
Last 92 transactions
Buy: 9 056 534 \| Sell: 550 582

Volume Correlation

Long: 0.16 (neutral)

Short: 0.52 (weak)

Signal:(46.248) Neutral

Poseida Therapeutics, Correlation

10 Most Positive Correlations
EUSGU	0.901
CVCY	0.897
AGNCM	0.884
MTRX	0.88
RING	0.879
TBNK	0.877
DOOO	0.875
VIOT	0.873
WINC	0.865
GTH	0.862

10 Most Negative Correlations
FAIL	-0.85
LLNW	-0.825
MBCN	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Poseida Therapeutics, Correlation - Currency/Commodity

-0.42
( neutral )

0.38
( neutral )

0.00
( neutral )

-0.60
( weak negative )

Poseida Therapeutics, Financials

Annual	2023
Revenue:	$64.70M
Gross Profit:	$64.70M (100.00 %)
EPS:	$-0.00140

Q4	2023
Revenue:	$25.00M
Gross Profit:	$20.82M (83.29 %)
EPS:	$-0.000300

Q3	2023
Revenue:	$9.35M
Gross Profit:	$7.91M (84.56 %)
EPS:	$-0.350

Q2	2023
Revenue:	$20.01M
Gross Profit:	$18.61M (92.96 %)
EPS:	$-0.320

Financial Reports:

No articles found.

Poseida Therapeutics,

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.